[1] Bartalena L, Baldeschi L, Boboridis K, et al.  The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26.   doi: 10.1159/000443828
[2] Douglas RS, Kahaly GJ, Patel A, et al.  Teprotumumab for the treatment of active thyroid eye disease[J]. N Engl J Med, 2020, 382(4): 341-352.   doi: 10.1056/NEJMoa1910434
[3] Smith TJ, Hegedus L.  Graves' disease[J]. N Engl J Med, 2016, 375(16): 1552-1565.   doi: 10.1056/NEJMra1510030
[4] 蒋承志, 李新辉, 邓豪余, 等.  99mTc-DTPA眼眶SPECT/CT显像非靶区及阈值的选择在甲状腺相关性眼病中的应用[J]. 中南大学学报: 医学版, 2018, 43(8): 869-874.   doi: 10.11817/j.issn.1672-7347.2018.08.008
Jiang CZ, Li XH, Deng HY, et al.  Nontarget area and threshold selection in 99mTc-DTPA orbital SPECT/CT imaging in thyroid associated ophthalmopathy[J]. J Cent South Univ: Med Sci, 2018, 43(8): 869-874.   doi: 10.11817/j.issn.1672-7347.2018.08.008
[5] 刘丹, 许雪亮, 文丹, 等.  99mTc-DTPA眼眶SPECT/CT对甲状腺相关性眼病炎性活动的评价[J]. 中南大学学报: 医学版, 2018, 43(4): 457-460.   doi: 10.11817/j.issn.1672-7347.2018.04.020
Liu D, Xu XL, Wen D, et al.  Evaluation of inflammatory activity in thyroid associated ophthalmopathy by SPECT/CT with 99mTc-DTPA[J]. J Cent South Univ (Med Sci), 2018, 43(4): 457-460.   doi: 10.11817/j.issn.1672-7347.2018.04.020
[6] Bartalena L, Baldeschi L, Dickinson A, et al.  Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO[J]. Eur J Endocrinol, 2008, 158(3): 273-285.   doi: 10.1530/EJE-07-0666
[7] Bartalena L, Baldeschi L, Dickinson AJ, et al.  Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy[J]. Thyroid, 2008, 18(3): 333-346.   doi: 10.1089/thy.2007.0315
[8] Galuska L, Barna SK, Varga J, et al.  The role of 99mTc-DTPA retrobulbar SPECT in staging and follow-up of Graves' orbitopathy[J]. Nucl Med Rev Cent East Eur, 2018, 21(1): 54-58.   doi: 10.5603/NMR.a2018.0005
[9]

Szumowski P, Abdelrazek S, Żukowski Ł, et al. Efficacy of 99mTc-DTPA SPECT/CT in diagnosing Orbitopathy in graves' disease[J/OL]. BMC Endocr Disord, 2019, 19(1): 10[2021-02-08]. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-019-0340-0. DOI: 10.1186/s12902-019-0340-0.
[10] Galuska L, Leovey A, Szucs-Farkas Z, et al.  SPECT using 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a comparison with the results from MRI[J]. Nucl Med Commun, 2002, 23(12): 1211-1216.   doi: 10.1097/00006231-200212000-00010